Dina Powell McCormick Resigns From Meta Board After Eight Months, May Take Advisory Role 
Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss 
Trump Administration Reviews Nvidia H200 Chip Sales to China, Marking Major Shift in U.S. AI Export Policy 
Mexico Antitrust Review of Viva Aerobus–Volaris Deal Signals Growth for Airline Sector 
Roche CEO Warns US Drug Price Deals Could Raise Costs of New Medicines in Switzerland 
John Carreyrou Sues Major AI Firms Over Alleged Copyrighted Book Use in AI Training 
JPMorgan’s Top Large-Cap Pharma Stocks to Watch in 2026 
FDA Fast-Tracks Approval of Altria’s on! PLUS Nicotine Pouches Under New Pilot Program 
FedEx Beats Q2 Earnings Expectations, Raises Full-Year Outlook Despite Stock Dip 
Warner Bros Discovery Weighs Amended Paramount Skydance Bid as Netflix Takeover Battle Intensifies 
U.S. Lawmakers Urge Pentagon to Blacklist More Chinese Tech Firms Over Military Ties 
FTC Praises Instacart for Ending AI Pricing Tests After $60M Settlement 
Italy Fines Apple €98.6 Million Over App Store Dominance 
Google and Apple Warn U.S. Visa Holders to Avoid International Travel Amid Lengthy Embassy Delays 
Moore Threads Unveils New GPUs, Fuels Optimism Around China’s AI Chip Ambitions 
TikTok U.S. Deal Advances as ByteDance Signs Binding Joint Venture Agreement 
Bridgewater Associates Plans Major Employee Ownership Expansion in Milestone Year 
RICHMOND, Calif., July 31, 2017 -- Ekso Bionics Holdings, Inc. (NASDAQ:EKSO), an industry leader in exoskeleton technology for medical and industrial use, today announced that it will release financial and business results for the second quarter 2017 after the close of trading on Monday, August 7, 2017. Management will host a conference call beginning at 1:30 p.m. PT / 4:30 p.m. ET to discuss the financial results and recent business developments.
Investors interested in listening to the conference call may do so by dialing (877) 407-3036 for domestic callers or (201)378-4919 for international callers, using Conference ID: 13581989. A live webcast of the event will be available in the “Investors” section of the company’s website at www.eksobionics.com, or by clicking here.
A replay of the call will be available for two weeks by dialing (877)660-6853 for domestic callers or (201)612-7415 for international callers and using Conference ID: 13581989. The webcast will also be available on the company’s website for one month following the completion of the call.
About Ekso Bionics®
Ekso Bionics is a leading developer of exoskeleton solutions that amplify human potential by supporting or enhancing strength, endurance and mobility across medical, industrial and defense applications. Founded in 2005, the company continues to build upon its unparalleled expertise to design some of the most cutting-edge, innovative wearable robots available on the market. Ekso Bionics is the only exoskeleton company to offer technologies that range from helping those with paralysis to stand up and walk, to enhancing human capabilities on job sites across the globe, to providing research for the advancement of R&D projects intended to benefit U.S. defense capabilities. The company is headquartered in the Bay Area and is listed on the Nasdaq Capital Market under the symbol EKSO. For more information, visit: www.eksobionics.com.
Media Contact: Carrie Yamond 917-371-2320 [email protected] Investor Contact: Matthew Ventimiglia 212-599-1265 [email protected]
